A computational drug discovery engine that transforms clinically validated natural product scaffolds into patent-pending drug candidates — targeting orphan diseases and companion animal health at a fraction of conventional cost and timeline.
Most drug discovery starts from blank chemistry. We don't. Our starting compounds come from pharmacopoeias with decades to centuries of documented clinical use — with published pharmacokinetic data, known safety profiles, and real biological signals. This dramatically reduces translational risk.
Rather than screening at random, the platform uses each compound's structure to guide targeted molecular improvements — designing better candidates, not just filtering existing ones.
Computational predictions are checked against real-world laboratory results, and each round of experimental feedback sharpens the platform's accuracy over time.
Our drug assets and the methods behind them are protected by multiple US provisional patent applications (filed; none granted to date).
We offer patent-pending drug assets ready for licensing, co-development, or regional partnership — across orphan CNS, pediatric neurology, oncology, and companion animal health.
Pipeline assets available for licensing in both human orphan disease and companion animal health indications.